 |
|
Managing Systemic Mycoses in the Compromised Host
Stephen D. Codish, MD;
Jeffrey S. Tobias, MRCP
JAMA. 1976;235(19):2132-2134.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
IMMUNOSUPPRESSIVE therapy is now being used more frequently as a result of its proved value in several areas of medicine. Infection secondary to impaired resistance is the major cause of morbidity and mortality in patients treated with these agents.1-5 Fatal infections following immunosuppression are most often seen in patients with advanced malignant disease or after transplantation, and the incidence of infection is greater in patients receiving steroids, antilymphocyte serum, and combination antineoplastic chemotherapy.2,4,5
Candida
Candida is the most frequently encountered fungus in cancer and transplant patients.2,6,7 Antibacterial agents have a special role in candidiasis since they increase colonization of the skin and mucous membranes with Candida species, particularly C albicans.8 Localizing symptoms of candidiasis are usually confined to the distal esophagus or bladder but sometimes result from endophthalmitis, meningitis, arthritis, perforation of an abdominal viscus, or emboli from endocarditis.8,9 Roentgenographic evidence of Candida pneumonitis typically
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Surgery, Harvard Medical School, Boston (Dr Codish), and the Department of Medical Oncology, St Bartholomew's Hospital, London (Dr Tobias).
Footnotes
Reprint requests to Department of Surgery, Harvard Medical School, Boston, MA 02115 (Dr Codish).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
